Skip to main content

Table 2 Summary of all 15 cases

From: Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution’s experience

Case Result of preoperative CNB Final pathology Method of surgery Chemotherapy Radiotherapy Endocrine therapy Follow-up (months) Recurrence
1 IDP AME carcinoma WLE + Tamoxifen 105
2 IDC AME carcinoma with DCIS BCS, SLNB +   105
3 AME tumor AME carcinoma TM, SLNB Adjuvant AC 4 cycles   72
4 AME carcinoma AME carcinoma WLE, SLNB Adjuvant TAC 6 cycles +   37
5 AME neoplasm AME carcinoma WLE +   33
6 Eccrine spiradenoma AME carcinoma WLE   20
7 Papillary neoplasm AME carcinoma WLE, SLNB + Tamoxifen 14
8 AME carcinoma AME carcinoma WLE + Tamoxifen 8
9 IDC AME carcinoma BCS, SLNB +   54
10 Papillary neoplasm AME carcinoma WLE + Tamoxifen 45
11 AME neoplasm AME carcinoma WLE +   33
12 AME neoplasm AME carcinoma WLE +   162 Local recurrence, lung metastasis
13 Sclerosing adenosis AME carcinoma WLE   111
14 Papillary neoplasm AME carcinoma WLE   5
15 IDC AME carcinoma TM, SLNB Neoadjuvant AC 4 cycles Tamoxifen 24 Lung metastasis
  1. AME Adenomyoepithelial, IDP Intraductal papilloma, IDC Invasive ductal carcinoma, WLE Wide local excision, BCS Breast conserving surgery, SLNB Sentinel lymph node biopsy, TM Total mastectomy, AC Adriamycin, cyclophosphamide, TAC Docetaxel (Taxotere), adriamycin, cyclophosphamide